We therefore evaluated the effectiveness of the CHK1i CCT244747 (a selective CHK1 inhibitor with a similar reported in vitro profile to SRA-737 [41]) in vivo by analysing its effect on the growth of five transplanted WT Eμ-Myc and Eμ-Myc/cRel−/− tumours. The gene discussed is MYC; the disease is neoplasm.